Takeda to buy T-Cell therapies developer Maverick for $525m
Takeda will obtain Maverick’s T-cell engager COBRA platform and its lead development candidates TAK-186 (MVC-101) and TAK-280 (MVC-280)
We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More X
10 Mar 21
Takeda will obtain Maverick’s T-cell engager COBRA platform and its lead development candidates TAK-186 (MVC-101) and TAK-280 (MVC-280)
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates
26 Feb 21
Takeda will continue to manufacture and supply the products under the sale to Teijin Pharma
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates
02 Feb 21
Horizon will benefit from Viela Bio’s Uplizna, and additional investigational drug candidates VIB4920, VIB7734, and VIB1116
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates
30 Dec 20
If the discussions are fruitful, Moderna is expected to supply 40 million doses of mRNA-1273 vaccine in South…
29 Dec 20
The generic glucagon is a synthetic version of human glucagon, a hormone that causes the liver to increase…
28 Dec 20
Covaxx, is currently conducting phase 1 clinical trial for the vaccine candidate
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates
22 Dec 20
The transaction includes Agios' marketed medicine Tibsovo and its oncology pipeline of Phase 3 and early-stage assets
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates
16 Dec 20
The acquisition will help Lilly establish a gene therapy programme, backed by Prevail's portfolio of neuroscience assets
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates
14 Dec 20
AstraZeneca would generate significant value from the acquisition by expanding Alexion's commercial reach and pipeline development
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates
11 Dec 20
With the acquisition, Gilead will get access to MYR’s advanced chronic Hepatitis Delta Virus (HDV) treatment Hepcludex
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates